Literature DB >> 20126471

c-Met overexpression contributes to the acquired apoptotic resistance of nonadherent ovarian cancer cells through a cross talk mediated by phosphatidylinositol 3-kinase and extracellular signal-regulated kinase 1/2.

Maggie K S Tang1, Hong Y Zhou, Judy W P Yam, Alice S T Wong.   

Abstract

Ovarian cancer is the most lethal gynecologic cancer mainly because of widespread peritoneal dissemination and malignant ascites. Key to this is the capacity of tumor cells to escape suspension-induced apoptosis (anoikis), which also underlies their resistance to chemotherapy. Here, we used a nonadherent cell culture model to investigate the molecular mechanisms of apoptotic resistance of ovarian cancer cells that may mimic the chemoresistance found in solid tumors. We found that ovarian cancer cells acquired a remarkable resistance to anoikis and apoptosis induced by exposure to clinically relevant doses of two front-line chemotherapeutic drugs cisplatin and paclitaxel when grown in three-dimensional than monolayer cultures. Inhibition of the hepatocyte growth factor (HGF) receptor c-Met, which is frequently overexpressed in ovarian cancer, by a specific inhibitor or small interfering RNA blocked the acquired anoikis resistance and restored chemosensitivity in three-dimensional not in two-dimensional cultures. These effects were found to be dependent on both phosphatidylinositol 3-kinase (PI3K)/Akt and extracellular signal-regulated kinase (ERK) 1/2 signaling pathways. Inhibitors of PI3K/Akt abrogated ERK1/2 activation and its associated anoikis resistance in response to HGF, suggesting a signaling relay between these two pathways. Furthermore, we identified a central role of Ras as a mechanism of this cross talk. Interestingly, Ras did not lie upstream of PI3K/Akt, whereas PI3K/Akt signaling to ERK1/2 involved Ras. These findings shed new light on the apoptotic resistance mechanism of nonadherent ovarian cancer ascites cells and may have important clinical implications.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20126471      PMCID: PMC2814351          DOI: 10.1593/neo.91438

Source DB:  PubMed          Journal:  Neoplasia        ISSN: 1476-5586            Impact factor:   5.715


  43 in total

Review 1.  Anoikis.

Authors:  A P Gilmore
Journal:  Cell Death Differ       Date:  2005-11       Impact factor: 15.828

2.  c-Met overexpression is a prognostic factor in ovarian cancer and an effective target for inhibition of peritoneal dissemination and invasion.

Authors:  Kenjiro Sawada; A Reza Radjabi; Nariyoshi Shinomiya; Emily Kistner; Hilary Kenny; Amy R Becker; Muge A Turkyilmaz; Ravi Salgia; S Diane Yamada; George F Vande Woude; Maria S Tretiakova; Ernst Lengyel
Journal:  Cancer Res       Date:  2007-02-15       Impact factor: 12.701

3.  EGF stimulates mesangial cell mitogenesis via PI3-kinase-mediated MAPK-dependent and AKT kinase-independent manner: involvement of c-fos and p27Kip1.

Authors:  Lenin Mahimainathan; Nandini Ghosh-Choudhury; Balachandar A Venkatesan; Ratna S Danda; Goutam Ghosh Choudhury
Journal:  Am J Physiol Renal Physiol       Date:  2005-02-08

4.  Cancer statistics, 2008.

Authors:  Ahmedin Jemal; Rebecca Siegel; Elizabeth Ward; Yongping Hao; Jiaquan Xu; Taylor Murray; Michael J Thun
Journal:  CA Cancer J Clin       Date:  2008-02-20       Impact factor: 508.702

5.  B-RAF and PI-3 kinase signaling protect melanoma cells from anoikis.

Authors:  K Boisvert-Adamo; A E Aplin
Journal:  Oncogene       Date:  2006-03-20       Impact factor: 9.867

6.  Cooperative effect of hepatocyte growth factor and fibronectin in anchorage-independent survival of mammary carcinoma cells: requirement for phosphatidylinositol 3-kinase activity.

Authors:  H Qiao; R Saulnier; A Patryzkat; N Rahimi; L Raptis; J Rossiter; E Tremblay; B Elliott
Journal:  Cell Growth Differ       Date:  2000-02

7.  Cross talk initiated by endothelial cells enhances migration and inhibits anoikis of squamous cell carcinoma cells through STAT3/Akt/ERK signaling.

Authors:  Kathleen G Neiva; Zhaocheng Zhang; Marta Miyazawa; Kristy A Warner; Elisabeta Karl; Jacques E Nör
Journal:  Neoplasia       Date:  2009-06       Impact factor: 5.715

8.  The plasticity of oncogene addiction: implications for targeted therapies directed to receptor tyrosine kinases.

Authors:  Vinochani Pillay; Layal Allaf; Alexander L Wilding; Jacqui F Donoghue; Naomi W Court; Steve A Greenall; Andrew M Scott; Terrance G Johns
Journal:  Neoplasia       Date:  2009-05       Impact factor: 5.715

9.  Epidermal growth factor induces phosphorylation of extracellular signal-regulated kinase 2 via multiple pathways.

Authors:  B M Burgering; A M de Vries-Smits; R H Medema; P C van Weeren; L G Tertoolen; J L Bos
Journal:  Mol Cell Biol       Date:  1993-12       Impact factor: 4.272

10.  Anti-apoptotic signaling by hepatocyte growth factor/Met via the phosphatidylinositol 3-kinase/Akt and mitogen-activated protein kinase pathways.

Authors:  G H Xiao; M Jeffers; A Bellacosa; Y Mitsuuchi; G F Vande Woude ; J R Testa
Journal:  Proc Natl Acad Sci U S A       Date:  2001-01-02       Impact factor: 11.205

View more
  54 in total

1.  The interconnectedness of cancer cell signaling.

Authors:  Alnawaz Rehemtulla
Journal:  Neoplasia       Date:  2011-12       Impact factor: 5.715

2.  Foretinib (GSK1363089), an orally available multikinase inhibitor of c-Met and VEGFR-2, blocks proliferation, induces anoikis, and impairs ovarian cancer metastasis.

Authors:  Marion Zillhardt; Sun-Mi Park; Iris L Romero; Kenjiro Sawada; Anthony Montag; Thomas Krausz; S Diane Yamada; Marcus E Peter; Ernst Lengyel
Journal:  Clin Cancer Res       Date:  2011-05-06       Impact factor: 12.531

3.  Combination of AKT inhibition with autophagy blockade effectively reduces ascites-derived ovarian cancer cell viability.

Authors:  Rohann J M Correa; Yudith Ramos Valdes; Teresa M Peart; Elena N Fazio; Monique Bertrand; Jacob McGee; Michel Préfontaine; Akira Sugimoto; Gabriel E DiMattia; Trevor G Shepherd
Journal:  Carcinogenesis       Date:  2014-02-22       Impact factor: 4.944

4.  Molecular determinants of response to PI3K/akt/mTOR and KRAS pathways inhibitors in NSCLC cell lines.

Authors:  Alice Iezzi; Elisa Caiola; Marika Colombo; Mirko Marabese; Massimo Broggini
Journal:  Am J Cancer Res       Date:  2020-12-01       Impact factor: 6.166

5.  Biological predictors of radiosensitivity in head and neck squamous cell carcinoma.

Authors:  Mathias Fiedler; Florian Weber; Matthias G Hautmann; Frank Haubner; Torsten E Reichert; Christoph Klingelhöffer; Stephan Schreml; Johannes K Meier; Arndt Hartmann; Tobias Ettl
Journal:  Clin Oral Investig       Date:  2017-03-18       Impact factor: 3.573

Review 6.  c-Met signaling in the development of tumorigenesis and chemoresistance: potential applications in pancreatic cancer.

Authors:  Daniel Delitto; Eva Vertes-George; Steven J Hughes; Kevin E Behrns; Jose G Trevino
Journal:  World J Gastroenterol       Date:  2014-07-14       Impact factor: 5.742

7.  Urinary cytokine and chemokine profiles across the menstrual cycle in healthy reproductive-aged women.

Authors:  Brian W Whitcomb; Sunni L Mumford; Neil J Perkins; Jean Wactawski-Wende; Elizabeth R Bertone-Johnson; Kristine E Lynch; Enrique F Schisterman
Journal:  Fertil Steril       Date:  2014-02-26       Impact factor: 7.329

8.  AKT/ERK activation is associated with gastric cancer cell resistance to paclitaxel.

Authors:  Gang Wu; Xue-Qian Qin; Jing-Jing Guo; Tian-Yi Li; Jin-Hong Chen
Journal:  Int J Clin Exp Pathol       Date:  2014-03-15

9.  Cellular responses to Cisplatin-induced DNA damage.

Authors:  Alakananda Basu; Soumya Krishnamurthy
Journal:  J Nucleic Acids       Date:  2010-08-08

Review 10.  Oncogenes associated with drug resistance in ovarian cancer.

Authors:  Xia Liu; Yutao Gao; Yi Lu; Jian Zhang; Li Li; Fuqiang Yin
Journal:  J Cancer Res Clin Oncol       Date:  2014-07-06       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.